Progastrin-releasing peptide: stability in plasma/serum and upper reference limit.
Nordlund MS, Bjerner J, Warren DJ, Nustad K, Paus E
Purpose
Conclusion
Studies (1)
Purpose
The purpose of this study was to determine the effects of patient characteristics, anticoagulant, tube type, storage, and protease inhibitors on the stability ProGRP measured by IFMA, in plasma and serum, from healthy individuals and patients with SCLC. The effects of acquisition and storage were investigated in 2-3 specimens, but the effects of preacquisition variables were investigated using 806 specimens.
Summary of Findings
Storage of serum or lithium heparin-plasma from 3 patients with SCLC, at room temperature, for 5 days resulted in decreased ProGRP levels, but storage of EDTA-plasma from 2 of the same 3 patients resulted in increasing ProGRP levels. In contrast, ProGRP levels remained relatively stable when plasma (EDTA or lithium heparin) and serum from 2-3 patients with SCLC were stored at 4 degrees C for up to 3 days and at -30 degrees C for the entire 4 weeks. When lithium heparin-plasma, EDTA-plasma, or serum from 2 healthy individuals were stored at 4 degrees C for 3 days, changes in ProGRP levels of up to 19%, 23% and 16% were observed, respectively. The authors report no effect of 3 freeze-thaw cycles on the levels of ProGRP in lithium heparin-plasma, EDTA-plasma, or serum from a single healthy individual and one patient with SCLC. Pefabloc completely stabilized exogenous ProGRP and partially stabilized endogenous ProGRP levels in serum stored at 4 degrees C for up to 2 weeks. Aprotinin, leupeptin and EDTA-Na2 partially stabilized ProGRP levels (exogenous and endogenous) in serum, but pepstatin and E64 did not improve stability of ProGRP during storage of serum at 4 degrees C. The authors report that time of collection, with respect to food consumption, had no effects on ProGRP levels, and levels in plain serum tubes and SST were also similar. High ProGRP levels in healthy individuals were associated with increasing age, increasing creatinine concentrations, decreasing BMI, being female, and smoking, but not alcohol consumption or physical activity.
Biospecimens
FluidPlasmaFluidSerumFluidBloodPreservation Types
None (Fresh)FrozenOther PreservativeDiagnoses
NormalNeoplasticCarcinomaPlatforms
ProteinImmunoassayPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Preaquisition Biomarker level 100-109 umol/L creatinine110-119 umol/L creatinine50-59 umol/L creatinine60-69 umol/L creatinine70-79 umol/L creatinine80-89 umol/L creatinine90-99 umol/L creatinine<49 umol/L creatinine>120 umol/L creatininePreaquisition Diagnosis/ patient condition NormalSmall cell lung cancerPreaquisition Other drugs 0 cigarettes/day0 units alcohol1-21 units alcohol1-5 cigarettes/day>21 units alcohol>5 cigarettes/dayPreaquisition Patient age 18-29 years30-39 year40-49 years50-59 years60-69 years70-79 years80-86 yearsPreaquisition Patient body mass index 20-24.925-29.9<19.9>30Preaquisition Patient gender FemaleMaleBiospecimen Acquisition Anticoagulant EDTALithium heparinNoneBiospecimen Acquisition Time of biospecimen collection 1 PM (after eating)10 AM (fasting)11 AM (before eating)3:45 (before eating)Biospecimen Acquisition Type of collection container/solution Plain serum tubeSSTBiospecimen Aliquots and Components Blood and blood products PlasmaSerumBiospecimen Preservation Type of fixation/preservation FrozenNone (fresh)RefrigerationStorage Freeze/thaw cycling 0 cycles1 cycle2 cycles3 cyclesStorage Storage duration 0 days1 day1 week2 weeks3 days3 weeks4 days4 weeks5 daysStorage Storage temperature -30 degrees C4 degrees CRoom temperatureAnalyte Extraction and Purification Protease inhibitor AprotininE-64LeupeptinPefablocPepstatinSodium EDTA